INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Rhea-AI Summary

INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancers, and infectious diseases, has scheduled the release of its fourth quarter and year-end 2024 financial results for March 18, 2025, after market close.

The company will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results and provide a business update. The webcast will include a Q&A session with analysts and will be available for replay for 90 days through the investor relations section of INOVIO's website.

News Market Reaction – INO

+5.13%

+5.13% Session move

In the trading session that priced this news, INO gained 5.13%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-18-2025-302400150.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When will INOVIO (INO) release its Q4 and full-year 2024 earnings?

INOVIO will release its Q4 and full-year 2024 financial results on March 18, 2025, after market close.

How can investors access INOVIO's Q4 2024 earnings call?

Investors can access the live webcast at 4:30 p.m. ET on March 18, 2025, through INOVIO's investor relations website.

How long will INOVIO's Q4 2024 earnings webcast be available for replay?

The earnings webcast will be archived and available for replay for 90 days following the event.

What areas does INOVIO focus on for its DNA medicines?

INOVIO focuses on developing DNA medicines for HPV-associated diseases, cancers, and infectious diseases.